首页> Annals of oncology : official journal of the European Society for Medical Oncology> A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors.

A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors.

导出原文传递

翻译打印收藏纠错

第一作者： R,Ferrarotto

第一单位： Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: rferrarotto@mdanderson.org.

作者： R,Ferrarotto ^[1] ; G,Eckhardt ^[2] ; A,Patnaik ^[3] ; P,LoRusso ^[4] ; L,Faoro ^[5] ; J V,Heymach ^[6] ; A M,Kapoun ^[5] ; L,Xu ^[5] ; P,Munster ^[7]

作者单位： Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: rferrarotto@mdanderson.org. ^[1] Division of Medical Oncology, University of Colorado Denver School of Medicine, Denver, USA. ^[2] Phase I Medical Oncology Program, South Texas Accelerated Research Therapeutics (START), San Antonio, USA. ^[3] Yale School of Medicine, Experimental Therapeutics, New Haven, USA. ^[4] OncoMed Pharmaceuticals Inc, Redwood City, USA. ^[5] Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. ^[6] Division of Hematology and Oncology, University of California San Francisco, San Francisco, USA. ^[7]